Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
162 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hemophilia A - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Hemophilia A - Pipeline Review, H2 2015', provides an overview of the Hemophilia A's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hemophilia A, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemophilia A and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hemophilia A - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemophilia A and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemophilia A products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemophilia A pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons To Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hemophilia A - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hemophilia A pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hemophilia A Overview 8 Therapeutics Development 9 Pipeline Products for Hemophilia A - Overview 9 Pipeline Products for Hemophilia A - Comparative Analysis 10 Hemophilia A - Therapeutics under Development by Companies 11 Hemophilia A - Therapeutics under Investigation by Universities/Institutes 15 Hemophilia A - Pipeline Products Glance 16 Late Stage Products 16 Clinical Stage Products 17 Early Stage Products 18 Unknown Stage Products 19 Hemophilia A - Products under Development by Companies 20 Hemophilia A - Products under Investigation by Universities/Institutes 23 Hemophilia A - Companies Involved in Therapeutics Development 24 Alnylam Pharmaceuticals, Inc. 24 Amarna Therapeutics B.V. 25 Apitope International NV 26 AstraZeneca Plc 27 Baxalta Incorporated 28 Bayer AG 29 Biogen, Inc. 30 BioMarin Pharmaceutical Inc. 31 Catalyst Biosciences, Inc. 32 Celtic Pharmaceutical Holdings L.P. 33 CSL Limited 34 DBV Technologies S.A. 35 Dimension Therapeutics, Inc. 36 Dong-A Socio Group 37 Emergent BioSolutions Inc. 38 EpiVax, Inc. 39 Expression Therapeutics LLC 40 F. Hoffmann-La Roche Ltd. 41 Green Cross Corporation 42 Inbiopro Solutions Pvt. Ltd. 43 Lentigen Technology, Inc. 44 mAbxience S.A. 45 Novo Nordisk A/S 46 OPKO Health, Inc. 47 Pfizer Inc. 48 Pharming Group N.V. 49 rEVO Biologics, Inc. 50 Sangamo BioSciences, Inc. 51 Selecta Biosciences, Inc. 52 SK Chemicals Co., Ltd. 53 Spark Therapeutics, Inc. 54 The International Biotechnology Center (IBC) Generium 55 uniQure N.V. 56 Hemophilia A - Therapeutics Assessment 57 Assessment by Monotherapy Products 57 Assessment by Target 58 Assessment by Mechanism of Action 60 Assessment by Route of Administration 62 Assessment by Molecule Type 64 Drug Profiles 66 antihemophilic factor - Drug Profile 66 antihemophilic factor (human) - Drug Profile 68 antihemophilic factor (recombinant) - Drug Profile 70 antihemophilic factor (recombinant) - Drug Profile 71 antihemophilic factor (recombinant) - Drug Profile 73 antihemophilic factor (recombinant) - Drug Profile 74 antihemophilic factor (recombinant) - Drug Profile 75 antihemophilic factor (recombinant) biosimilar - Drug Profile 76 ATXF-8117 - Drug Profile 77 AZ-10047130 - Drug Profile 78 BAX-826 - Drug Profile 79 BAX-888 - Drug Profile 80 BAY-1093884 - Drug Profile 81 BAY-818973 - Drug Profile 82 BMN-270 - Drug Profile 83 CB-813d - Drug Profile 84 coagulation factor VIIa (recombinant) - Drug Profile 86 concizumab - Drug Profile 88 CSL-689 - Drug Profile 89 damoctocog alfa pegol - Drug Profile 91 Deimmunized FVIII - Drug Profile 92 DTX-201 - Drug Profile 94 ET-3 - Drug Profile 95 factor VIII (recombinant) biosimilar - Drug Profile 96 Gene Therapy for Bleeding and Clotting Disorders - Drug Profile 97 Gene Therapy for Hemophilia A - Drug Profile 98 Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 99 GNR-022 - Drug Profile 100 IBPH-001OC - Drug Profile 101 LG-889 - Drug Profile 102 LR-769 - Drug Profile 103 MOD-5014 - Drug Profile 105 PF-06741086 - Drug Profile 107 Protein for Hemophilia A - Drug Profile 108 Proteins for Hemophilia A - Drug Profile 109 Recombinant Protein for Hemophilia A - Drug Profile 110 Recombinant Protein to Replace Factor VIII for Hemophilia A - Drug Profile 111 Recombinant Protein to Replace Factor VIII for Hemophilia A - Drug Profile 112 RG-6013 - Drug Profile 113 SAR-439774 - Drug Profile 114 SB-FVIII - Drug Profile 115 SEL-201 - Drug Profile 116 SPK-FVIII - Drug Profile 117 SVF-VIIa - Drug Profile 118 turoctocog alfa pegol - Drug Profile 119 Hemophilia A - Recent Pipeline Updates 121 Hemophilia A - Dormant Projects 147 Hemophilia A - Discontinued Products 149 Hemophilia A - Product Development Milestones 150 Featured News & Press Releases 150 Appendix 158 Methodology 158 Coverage 158 Secondary Research 158 Primary Research 158 Expert Panel Validation 158 Contact Us 158 Disclaimer 159
List of Tables
Number of Products under Development for Hemophilia A, H2 2015 12 Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2015 13 Number of Products under Development by Companies, H2 2015 15 Number of Products under Development by Companies, H2 2015 (Contd..1) 16 Number of Products under Development by Companies, H2 2015 (Contd..2) 17 Number of Products under Investigation by Universities/Institutes, H2 2015 18 Comparative Analysis by Late Stage Development, H2 2015 19 Comparative Analysis by Clinical Stage Development, H2 2015 20 Comparative Analysis by Early Stage Development, H2 2015 21 Comparative Analysis by Unknown Stage Development, H2 2015 22 Products under Development by Companies, H2 2015 23 Products under Development by Companies, H2 2015 (Contd..1) 24 Products under Development by Companies, H2 2015 (Contd..2) 25 Products under Investigation by Universities/Institutes, H2 2015 26 Hemophilia A - Pipeline by Alnylam Pharmaceuticals, Inc., H2 2015 27 Hemophilia A - Pipeline by Amarna Therapeutics B.V., H2 2015 28 Hemophilia A - Pipeline by Apitope International NV, H2 2015 29 Hemophilia A - Pipeline by AstraZeneca Plc, H2 2015 30 Hemophilia A - Pipeline by Baxalta Incorporated, H2 2015 31 Hemophilia A - Pipeline by Bayer AG, H2 2015 32 Hemophilia A - Pipeline by Biogen, Inc., H2 2015 33 Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc., H2 2015 34 Hemophilia A - Pipeline by Catalyst Biosciences, Inc., H2 2015 35 Hemophilia A - Pipeline by Celtic Pharmaceutical Holdings L.P., H2 2015 36 Hemophilia A - Pipeline by CSL Limited, H2 2015 37 Hemophilia A - Pipeline by DBV Technologies S.A., H2 2015 38 Hemophilia A - Pipeline by Dimension Therapeutics, Inc., H2 2015 39 Hemophilia A - Pipeline by Dong-A Socio Group, H2 2015 40 Hemophilia A - Pipeline by Emergent BioSolutions Inc., H2 2015 41 Hemophilia A - Pipeline by EpiVax, Inc., H2 2015 42 Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2015 43 Hemophilia A - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 44 Hemophilia A - Pipeline by Green Cross Corporation, H2 2015 45 Hemophilia A - Pipeline by Inbiopro Solutions Pvt. Ltd., H2 2015 46 Hemophilia A - Pipeline by Lentigen Technology, Inc., H2 2015 47 Hemophilia A - Pipeline by mAbxience S.A., H2 2015 48 Hemophilia A - Pipeline by Novo Nordisk A/S, H2 2015 49 Hemophilia A - Pipeline by OPKO Health, Inc., H2 2015 50 Hemophilia A - Pipeline by Pfizer Inc., H2 2015 51 Hemophilia A - Pipeline by Pharming Group N.V., H2 2015 52 Hemophilia A - Pipeline by rEVO Biologics, Inc., H2 2015 53 Hemophilia A - Pipeline by Sangamo BioSciences, Inc., H2 2015 54 Hemophilia A - Pipeline by Selecta Biosciences, Inc., H2 2015 55 Hemophilia A - Pipeline by SK Chemicals Co., Ltd., H2 2015 56 Hemophilia A - Pipeline by Spark Therapeutics, Inc., H2 2015 57 Hemophilia A - Pipeline by The International Biotechnology Center (IBC) Generium, H2 2015 58 Hemophilia A - Pipeline by uniQure N.V., H2 2015 59 Assessment by Monotherapy Products, H2 2015 60 Number of Products by Stage and Target, H2 2015 62 Number of Products by Stage and Mechanism of Action, H2 2015 64 Number of Products by Stage and Route of Administration, H2 2015 66 Number of Products by Stage and Molecule Type, H2 2015 68 Hemophilia A Therapeutics - Recent Pipeline Updates, H2 2015 124 Hemophilia A - Dormant Projects, H2 2015 150 Hemophilia A - Dormant Projects (Contd..1), H2 2015 151 Hemophilia A - Discontinued Products, H2 2015 152
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
